Henan Tianfu Chemical Co., Ltd.
Country: China (Mainland)
Year Established: 2006
Business License:
Business type: Lab/Research institutions
Contact Details | Similar Products

Communicate with Supplier:

: Mr. Anson: What can I do for you?

Tofacitinib citrate 540737-29-9 CAS NO.540737-29-9

Min.Order Quantity:: 1 Kilogram

Purity:: 99%

Port:: any port in china

Payment Terms:: L/C,T/T,

Add to Inquiry Cart

Product Details

Keywords

540737-29-9
Tofacitinib citrate
C16H20N6O.C6H8O7

Quick Details

ProName: Tofacitinib citrate 540737-29-9
CasNo: 540737-29-9
Molecular Formula: C16H20N6O.C6H8O7
Appearance: conform
Application: 540737-29-9
DeliveryTime: within 7 days after PO
PackAge: normal package
Port: any port in china
ProductionCapacity: 1 Metric Ton/Day
Purity: 99%
Storage: conform
Transportation: by air
LimitNum: 1 Kilogram
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

our company was built in 2009 with an iso certificate.in the past 5 years, we have grown up as a famous fine chemicals supplier in china and we had established stable business relationships with samsung,lg,merck,thermo fisher scientific and so on.our main business covers the fields below:

1.noble metal catalysts (pt.pd...)

2.organic phosphine ligands (tert-butyl-phosphine.cyclohexyl-phosphine...)

3.oled intermediates (fluorene,carbazole,boric acid...)

4.customs synthesis

our advantage:

1. higest quality and good package

2.fast delivery

3.better payment term

4.fast response to customer within 6 hours

5.good business credit in europe ,us ,japan ,korea

anyway ,if you need any chemicals from china ,henan tianfu can help you

Details

tofacitinib citrate basic information

drug fortreatment of rheumatoid arthritis application

product name:	tofacitinib citrate
synonyms:	1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);tofacitinib citrate (cp-690550);tofacitinib citrate;tasocitinib citrate;tasocitinib citric acid s...;xeljanz;cp-690550 (tofacitinib citrate)
cas:	540737-29-9
mf:	c16h20n6o.c6h8o7
mw:	504.497
einecs:
product categories:	inhibitor;inhibitors
mol file:	540737-29-9.mol

tofacitinib citrate chemical properties

storage temp.

room temp

safety information

msds information

tofacitinib citrate usage and synthesis

drug fortreatment of rheumatoid arthritis

tofacitinib citrate is a king of drugs developed by the us pharmaceutical company pfizer for treating rheumatoid arthritis , trade name xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis ( ra) in adult patients. this product is a janus kinase inhibitor, administered twice daily.
november 6, 2012, the us food and drug administration (fda) and pfizer jointly announced tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (ra) in adult patients.
xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the dmard) in combination. this medicine should not be in combination with biological dmard or strong immunosuppressants (such as cyclosporine and azathioprine) . xeljanz is approved by the daily dose of 2 times, each time 5mg.
seven clinical trials evaluated the safety and efficacy of tofacitinib citrate in moderate to severe active ra in adult patients. in all tests, compared with patients receiving placebo, patients receiving xeljanz treatment showed significant improvement in clinical response and physical function.
in clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
using xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. xeljanz product label attaches boxed warning on these security risks . xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
in order to study xeljanz long-term impact on heart disease, cancer and severe infections, fda requires for a post-marketing study, which will evaluate two doses of xeljanz (tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.
the above information is edited by the chemicalbook of tian ye.

application

jak kinase inhibitor, to treat rheumatoid arthritis.
tropsch erlotinib (477600-75-2) bulk pharmaceutical chemicals.

Post a RFQ

Cas No.:

Product Name:

Quantity: